VOX Vox Valor Capital Limited

RNS Number:0780V
VASTox plc
18 April 2007


                                   VASTox plc
                          ("VASTox" or "the Company")


                          Additional Listing of Shares


Oxford, UK, 18 April 2007 -Application has today been made for 505,430 ordinary
shares of 10p each in the Company ("Ordinary Shares") to be admitted to trading
on the London Stock Exchange's AIM market for listed securities ("Admission").

The new Ordinary Shares are being issued pursuant to the exercise of options by
former employees of DanioLabs Limited. Admission is expected to become effective
on 24 April 2007.

Following the admission of these shares the total number of Ordinary Shares in
issue will be 49,625,941 Ordinary Shares.


                                    - ends -


For more information, please contact:

VASTox
Steven Lee, PhD, Chief Executive Officer          Tel: +44 (0)1235 443951
Darren Millington, Chief Financial Officer

Citigate Dewe Rogerson
Mark Swallow / David Dible / Valerie Auffray      Tel: +44 (0)207 638 9571


About VASTox plc

VASTox is a leading UK biotechnology company that discovers and develops
proprietary new drugs. The Company's internal drug development programmes are
underpinned by its advanced chemistry and drug screening (chemical genomics)
technology platforms, which it also provides on a collaborative or
fee-for-service basis to the pharmaceutical industry.

VASTox has a broad range of drug discovery programmes in the clinical,
pre-clinical and discovery stages of development, which target serious diseases
with a high unmet medical need. These therapeutic areas include neuro-disorders
(neurodegenerative and neuromuscular), anti-infectives, ophthalmic diseases,
oncology and regenerative medicines.

VASTox's in-house drug development capabilities combine world-class expertise in
both medicinal and carbohydrate chemistry with high-volume, high-content
screening using its proprietary zebrafish and fruitfly technologies (chemical
genomics). These whole organism screens have the potential to dramatically
decrease the time and cost of drug discovery and development by delivering data
that are highly predictive of the efficacy and toxicity of potential drug
compounds in humans.

The company listed on the AIM market of the London Stock Exchange in October
2004 - symbol: VOX

Further information about the company is available at www.vastox.com




                      This information is provided by RNS
            The company news service from the London Stock Exchange

END
LISGUUBGCUPMGPR

Grafico Azioni Vox Valor Capital (LSE:VOX)
Storico
Da Mag 2024 a Giu 2024

Grafico Azioni Vox Valor Capital (LSE:VOX)
Storico
Da Giu 2023 a Giu 2024